Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Proto-Oncogene Proteins B-raf | 18 | 2023 | 2028 | 2.810 |
Why?
|
Colorectal Neoplasms | 27 | 2023 | 6754 | 2.550 |
Why?
|
Drug Resistance, Neoplasm | 22 | 2023 | 5163 | 2.500 |
Why?
|
MAP Kinase Kinase 1 | 5 | 2020 | 337 | 2.280 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 13 | 2023 | 1683 | 2.240 |
Why?
|
Protein Kinase Inhibitors | 21 | 2024 | 5522 | 1.910 |
Why?
|
MAP Kinase Signaling System | 9 | 2019 | 1525 | 1.860 |
Why?
|
Gastrointestinal Neoplasms | 7 | 2023 | 987 | 1.670 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 7 | 2023 | 647 | 1.280 |
Why?
|
Mutation | 34 | 2024 | 29717 | 1.190 |
Why?
|
raf Kinases | 2 | 2019 | 122 | 1.060 |
Why?
|
DNA, Neoplasm | 7 | 2019 | 1758 | 1.030 |
Why?
|
Gene Amplification | 6 | 2020 | 1062 | 0.940 |
Why?
|
Antineoplastic Agents | 13 | 2021 | 13655 | 0.850 |
Why?
|
Neoplasms | 15 | 2022 | 21596 | 0.780 |
Why?
|
Acetonitriles | 1 | 2021 | 52 | 0.780 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 11472 | 0.760 |
Why?
|
ras Proteins | 7 | 2019 | 1060 | 0.750 |
Why?
|
Pyrimidinones | 5 | 2023 | 370 | 0.700 |
Why?
|
Pyridones | 5 | 2023 | 712 | 0.590 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 974 | 0.590 |
Why?
|
Benzimidazoles | 3 | 2014 | 848 | 0.580 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 578 | 0.560 |
Why?
|
Sulfonamides | 4 | 2013 | 1932 | 0.550 |
Why?
|
Medulloblastoma | 3 | 2008 | 681 | 0.540 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 732 | 0.540 |
Why?
|
Pyrimidines | 5 | 2021 | 2933 | 0.540 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 4 | 2024 | 187 | 0.530 |
Why?
|
Molecular Targeted Therapy | 9 | 2021 | 2723 | 0.520 |
Why?
|
Cholangiocarcinoma | 4 | 2024 | 516 | 0.510 |
Why?
|
Cell Line, Tumor | 18 | 2022 | 16665 | 0.500 |
Why?
|
Piperazines | 2 | 2021 | 2488 | 0.450 |
Why?
|
MAP Kinase Kinase Kinases | 2 | 2014 | 261 | 0.420 |
Why?
|
Oximes | 3 | 2020 | 309 | 0.420 |
Why?
|
Pyridines | 2 | 2021 | 2818 | 0.420 |
Why?
|
bcl-X Protein | 2 | 2013 | 411 | 0.420 |
Why?
|
Melanoma | 3 | 2023 | 5462 | 0.410 |
Why?
|
Carcinoma, Pancreatic Ductal | 4 | 2021 | 1631 | 0.410 |
Why?
|
Aniline Compounds | 2 | 2013 | 983 | 0.390 |
Why?
|
Bile Duct Neoplasms | 3 | 2024 | 567 | 0.390 |
Why?
|
Rectal Neoplasms | 4 | 2021 | 1195 | 0.390 |
Why?
|
Imidazoles | 4 | 2020 | 1205 | 0.390 |
Why?
|
Pancreatic Neoplasms | 7 | 2021 | 5249 | 0.370 |
Why?
|
Stomach Neoplasms | 2 | 2020 | 1327 | 0.370 |
Why?
|
Cerebellar Neoplasms | 2 | 2008 | 585 | 0.370 |
Why?
|
Multiprotein Complexes | 2 | 2013 | 1119 | 0.360 |
Why?
|
Esophageal Neoplasms | 2 | 2020 | 1581 | 0.360 |
Why?
|
Humans | 85 | 2024 | 742088 | 0.340 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2019 | 3557 | 0.330 |
Why?
|
Genes, ras | 1 | 2011 | 691 | 0.320 |
Why?
|
Oncogene Protein p21(ras) | 2 | 2019 | 82 | 0.300 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3585 | 0.300 |
Why?
|
Signal Transduction | 12 | 2024 | 23387 | 0.300 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2013 | 2107 | 0.300 |
Why?
|
Feedback | 2 | 2022 | 793 | 0.300 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2008 | 271 | 0.290 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 5171 | 0.290 |
Why?
|
Indoles | 2 | 2013 | 1834 | 0.290 |
Why?
|
STAT3 Transcription Factor | 1 | 2011 | 874 | 0.290 |
Why?
|
Sterols | 1 | 2006 | 63 | 0.280 |
Why?
|
Immunoconjugates | 2 | 2023 | 897 | 0.250 |
Why?
|
Precancerous Conditions | 1 | 2011 | 971 | 0.240 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2024 | 2938 | 0.230 |
Why?
|
Mice, Nude | 6 | 2018 | 3689 | 0.220 |
Why?
|
Neoplasm Metastasis | 4 | 2021 | 4839 | 0.210 |
Why?
|
Mice | 19 | 2022 | 81045 | 0.210 |
Why?
|
Heterozygote | 1 | 2008 | 2790 | 0.200 |
Why?
|
Receptors, Cell Surface | 3 | 2009 | 2867 | 0.200 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 248 | 0.200 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2011 | 2940 | 0.200 |
Why?
|
Microsatellite Repeats | 2 | 2021 | 800 | 0.200 |
Why?
|
Animals | 26 | 2022 | 168561 | 0.200 |
Why?
|
Basal Cell Nevus Syndrome | 1 | 2001 | 40 | 0.200 |
Why?
|
Lung Neoplasms | 4 | 2021 | 13019 | 0.190 |
Why?
|
Neoadjuvant Therapy | 3 | 2021 | 2721 | 0.190 |
Why?
|
DNA Mismatch Repair | 2 | 2021 | 424 | 0.190 |
Why?
|
Hematologic Tests | 1 | 2021 | 238 | 0.180 |
Why?
|
Survival Rate | 5 | 2020 | 12773 | 0.180 |
Why?
|
Papillomavirus Infections | 2 | 2022 | 1585 | 0.180 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4249 | 0.180 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2020 | 2638 | 0.180 |
Why?
|
Immune Evasion | 1 | 2023 | 360 | 0.170 |
Why?
|
RNA Editing | 1 | 2020 | 148 | 0.170 |
Why?
|
Prognosis | 8 | 2021 | 29010 | 0.170 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 221 | 0.170 |
Why?
|
Retinoblastoma Protein | 1 | 2022 | 701 | 0.160 |
Why?
|
Oncogenes | 3 | 2019 | 1263 | 0.160 |
Why?
|
Trans-Activators | 2 | 2006 | 2924 | 0.160 |
Why?
|
Cytidine Deaminase | 1 | 2020 | 251 | 0.160 |
Why?
|
Head and Neck Neoplasms | 2 | 2022 | 2712 | 0.160 |
Why?
|
Phosphorylation | 4 | 2016 | 8436 | 0.150 |
Why?
|
Immunotherapy | 3 | 2023 | 4414 | 0.150 |
Why?
|
Transcriptional Activation | 3 | 2015 | 1782 | 0.150 |
Why?
|
Losartan | 1 | 2019 | 298 | 0.150 |
Why?
|
Phenylurea Compounds | 2 | 2019 | 526 | 0.150 |
Why?
|
Female | 32 | 2024 | 379592 | 0.150 |
Why?
|
Medical Oncology | 2 | 2020 | 2235 | 0.150 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2022 | 1284 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2021 | 8425 | 0.150 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2016 | 731 | 0.140 |
Why?
|
Radiation Tolerance | 1 | 2019 | 484 | 0.140 |
Why?
|
Treatment Outcome | 10 | 2021 | 62966 | 0.140 |
Why?
|
Proto-Oncogene Proteins | 6 | 2015 | 4553 | 0.140 |
Why?
|
Japan | 1 | 2020 | 1360 | 0.140 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2022 | 475 | 0.140 |
Why?
|
Biopsy | 2 | 2020 | 6756 | 0.140 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2020 | 880 | 0.130 |
Why?
|
Autopsy | 1 | 2019 | 1006 | 0.130 |
Why?
|
Cytomegalovirus | 1 | 2020 | 730 | 0.130 |
Why?
|
Mutation, Missense | 2 | 2018 | 2556 | 0.130 |
Why?
|
Middle Aged | 21 | 2021 | 213127 | 0.130 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2016 | 250 | 0.130 |
Why?
|
Adenocarcinoma | 3 | 2021 | 6347 | 0.130 |
Why?
|
Canada | 1 | 2020 | 2061 | 0.120 |
Why?
|
Standard of Care | 1 | 2018 | 562 | 0.120 |
Why?
|
Pyridazines | 1 | 2016 | 201 | 0.120 |
Why?
|
Receptor, erbB-2 | 3 | 2023 | 2410 | 0.120 |
Why?
|
Male | 25 | 2023 | 349538 | 0.120 |
Why?
|
Oxygen | 1 | 2006 | 4169 | 0.120 |
Why?
|
Aged | 17 | 2021 | 162944 | 0.120 |
Why?
|
Antibodies | 2 | 2020 | 2459 | 0.120 |
Why?
|
Morpholines | 2 | 2014 | 561 | 0.120 |
Why?
|
Ribosomal Protein S6 | 1 | 2013 | 70 | 0.120 |
Why?
|
Colonic Neoplasms | 2 | 2023 | 2542 | 0.110 |
Why?
|
Exons | 1 | 2019 | 2431 | 0.110 |
Why?
|
Mutant Proteins | 2 | 2016 | 500 | 0.110 |
Why?
|
Autocrine Communication | 1 | 2014 | 171 | 0.110 |
Why?
|
Leucovorin | 3 | 2021 | 624 | 0.110 |
Why?
|
Hedgehog Proteins | 2 | 2009 | 781 | 0.110 |
Why?
|
Adenosine Triphosphate | 1 | 2019 | 2024 | 0.110 |
Why?
|
Microsatellite Instability | 1 | 2015 | 678 | 0.100 |
Why?
|
Genomics | 2 | 2018 | 5692 | 0.100 |
Why?
|
Carcinoma | 1 | 2023 | 2374 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2019 | 933 | 0.100 |
Why?
|
Blotting, Western | 2 | 2010 | 5180 | 0.100 |
Why?
|
Antigen Presentation | 1 | 2017 | 1284 | 0.100 |
Why?
|
HT29 Cells | 1 | 2012 | 200 | 0.100 |
Why?
|
Gene Dosage | 1 | 2016 | 1251 | 0.100 |
Why?
|
Membrane Proteins | 3 | 2015 | 7873 | 0.100 |
Why?
|
Aged, 80 and over | 8 | 2021 | 57683 | 0.100 |
Why?
|
Cohort Studies | 6 | 2023 | 40450 | 0.100 |
Why?
|
Cell Growth Processes | 1 | 2012 | 400 | 0.100 |
Why?
|
Antibodies, Monoclonal | 3 | 2017 | 9274 | 0.100 |
Why?
|
Mice, SCID | 2 | 2019 | 2715 | 0.100 |
Why?
|
Chromatin | 1 | 2022 | 2917 | 0.090 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 625 | 0.090 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 2009 | 1221 | 0.090 |
Why?
|
Influenza Vaccines | 1 | 1997 | 733 | 0.090 |
Why?
|
Inhibitory Concentration 50 | 1 | 2010 | 459 | 0.090 |
Why?
|
Fluorouracil | 3 | 2021 | 1615 | 0.090 |
Why?
|
Weight Loss | 1 | 2021 | 2604 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2015 | 1144 | 0.090 |
Why?
|
DNA Primers | 2 | 2011 | 2892 | 0.090 |
Why?
|
Prospective Studies | 5 | 2021 | 53187 | 0.090 |
Why?
|
DNA Damage | 1 | 2019 | 2423 | 0.080 |
Why?
|
Proteins | 2 | 2023 | 6096 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11001 | 0.080 |
Why?
|
Benzamides | 1 | 2014 | 1378 | 0.080 |
Why?
|
Adult | 13 | 2021 | 213712 | 0.080 |
Why?
|
Quality of Life | 3 | 2023 | 12730 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4823 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4438 | 0.070 |
Why?
|
Influenza, Human | 1 | 1997 | 1472 | 0.070 |
Why?
|
Disease Progression | 2 | 2020 | 13256 | 0.070 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2011 | 1158 | 0.070 |
Why?
|
Down-Regulation | 1 | 2013 | 3001 | 0.070 |
Why?
|
Papillomaviridae | 2 | 2022 | 1118 | 0.070 |
Why?
|
Transcription, Genetic | 3 | 2021 | 7721 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 9410 | 0.070 |
Why?
|
Vaccination | 1 | 1997 | 3256 | 0.060 |
Why?
|
Treatment Failure | 1 | 2011 | 2615 | 0.060 |
Why?
|
Ireland | 3 | 2002 | 160 | 0.060 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2024 | 890 | 0.060 |
Why?
|
RNA, Small Interfering | 2 | 2011 | 3504 | 0.060 |
Why?
|
Cell Proliferation | 3 | 2016 | 10472 | 0.060 |
Why?
|
In Situ Hybridization | 1 | 2008 | 1950 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 3070 | 0.060 |
Why?
|
DNA Methylation | 1 | 2018 | 4282 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2021 | 9185 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1659 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2020 | 13921 | 0.060 |
Why?
|
Immunohistochemistry | 2 | 2019 | 11363 | 0.060 |
Why?
|
Tumor Necrosis Factors | 1 | 2023 | 109 | 0.060 |
Why?
|
Genetic Variation | 1 | 2018 | 6540 | 0.050 |
Why?
|
Pediatrics | 1 | 2018 | 3462 | 0.050 |
Why?
|
Neoplasms, Experimental | 3 | 2017 | 1274 | 0.050 |
Why?
|
Cell Line | 4 | 2020 | 15994 | 0.050 |
Why?
|
Mice, Transgenic | 2 | 2014 | 9735 | 0.050 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2024 | 295 | 0.050 |
Why?
|
Carcinoembryonic Antigen | 1 | 2023 | 347 | 0.050 |
Why?
|
Apoptosis | 3 | 2013 | 9715 | 0.050 |
Why?
|
E2F1 Transcription Factor | 1 | 2022 | 190 | 0.050 |
Why?
|
STAT Transcription Factors | 1 | 2023 | 182 | 0.050 |
Why?
|
E2F Transcription Factors | 1 | 2022 | 274 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2010 | 6365 | 0.050 |
Why?
|
Janus Kinases | 1 | 2023 | 244 | 0.050 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2023 | 338 | 0.050 |
Why?
|
Molecular Structure | 1 | 2006 | 1907 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 160 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2019 | 6313 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4751 | 0.050 |
Why?
|
Lamivudine | 1 | 2022 | 342 | 0.050 |
Why?
|
Transcription Factor AP-1 | 1 | 2022 | 317 | 0.050 |
Why?
|
Spheroids, Cellular | 1 | 2023 | 351 | 0.050 |
Why?
|
Cell Compartmentation | 1 | 2021 | 402 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2022 | 2948 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3920 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20086 | 0.040 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2002 | 392 | 0.040 |
Why?
|
Caspases | 1 | 2023 | 928 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6259 | 0.040 |
Why?
|
Enzyme Assays | 1 | 2020 | 111 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 4801 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2020 | 281 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12220 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 704 | 0.040 |
Why?
|
Esophagogastric Junction | 1 | 2020 | 312 | 0.040 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3444 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39004 | 0.040 |
Why?
|
Growth Substances | 1 | 2000 | 783 | 0.040 |
Why?
|
Matrix Metalloproteinases | 1 | 2020 | 391 | 0.040 |
Why?
|
Transcription Factor TFIIIA | 1 | 2016 | 25 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2018 | 8829 | 0.040 |
Why?
|
Chemokines | 1 | 2021 | 954 | 0.040 |
Why?
|
beta 2-Microglobulin | 1 | 2017 | 315 | 0.040 |
Why?
|
Young Adult | 2 | 2021 | 56350 | 0.040 |
Why?
|
Organoids | 1 | 2023 | 692 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2021 | 804 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 105 | 0.040 |
Why?
|
Breast Neoplasms | 1 | 2024 | 20774 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 838 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 707 | 0.030 |
Why?
|
Immunomodulation | 1 | 2020 | 540 | 0.030 |
Why?
|
Stromal Cells | 1 | 2021 | 1353 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2000 | 749 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2303 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2017 | 678 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1011 | 0.030 |
Why?
|
DNA, Viral | 1 | 2022 | 2224 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 7901 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2019 | 1875 | 0.030 |
Why?
|
Family Practice | 1 | 1997 | 516 | 0.030 |
Why?
|
Radiotherapy | 1 | 2021 | 1525 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2016 | 18006 | 0.030 |
Why?
|
Models, Biological | 1 | 2011 | 9581 | 0.030 |
Why?
|
Outpatients | 1 | 2002 | 1483 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2023 | 3199 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2000 | 1363 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6474 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2015 | 286 | 0.030 |
Why?
|
Gene Fusion | 1 | 2016 | 371 | 0.030 |
Why?
|
Feedback, Physiological | 1 | 2016 | 479 | 0.030 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 5867 | 0.030 |
Why?
|
Zebrafish Proteins | 1 | 2000 | 1004 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2021 | 77098 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2020 | 1366 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2019 | 3133 | 0.030 |
Why?
|
Chemokine CCL5 | 1 | 2014 | 209 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2015 | 408 | 0.030 |
Why?
|
I-kappa B Proteins | 1 | 2014 | 225 | 0.030 |
Why?
|
Codon | 1 | 2015 | 611 | 0.030 |
Why?
|
Patient Satisfaction | 2 | 2002 | 3391 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1575 | 0.030 |
Why?
|
Point Mutation | 1 | 2017 | 1624 | 0.030 |
Why?
|
Colon | 1 | 2020 | 1773 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2747 | 0.030 |
Why?
|
Monocytes | 1 | 2021 | 2593 | 0.030 |
Why?
|
Confidence Intervals | 1 | 1997 | 2970 | 0.030 |
Why?
|
Clone Cells | 1 | 2015 | 1692 | 0.030 |
Why?
|
Quality Indicators, Health Care | 1 | 2002 | 1831 | 0.030 |
Why?
|
Camptothecin | 1 | 2015 | 572 | 0.020 |
Why?
|
GTP Phosphohydrolases | 1 | 2015 | 508 | 0.020 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2011 | 92 | 0.020 |
Why?
|
RNA Interference | 1 | 2020 | 2890 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1983 | 0.020 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1255 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2019 | 1581 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1028 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2020 | 4200 | 0.020 |
Why?
|
Aminopyridines | 1 | 2014 | 541 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2906 | 0.020 |
Why?
|
Cell Death | 1 | 2016 | 1695 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 6382 | 0.020 |
Why?
|
Drug Synergism | 1 | 2014 | 1791 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1786 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2013 | 1866 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2011 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2016 | 3701 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 2978 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1707 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 17400 | 0.020 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2000 | 1461 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3711 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2020 | 5519 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2042 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2017 | 14554 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3455 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2450 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8297 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7289 | 0.020 |
Why?
|
Quinazolines | 1 | 2014 | 1355 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8662 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2011 | 2085 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3564 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1655 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1434 | 0.020 |
Why?
|
Genetic Testing | 1 | 2019 | 3439 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2021 | 4933 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2015 | 6171 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15056 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 1997 | 5385 | 0.020 |
Why?
|
Child | 3 | 2023 | 77478 | 0.020 |
Why?
|
Alleles | 1 | 2015 | 6931 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2014 | 3199 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10163 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2382 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 20928 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 2502 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10578 | 0.010 |
Why?
|
CCN Intercellular Signaling Proteins | 1 | 2000 | 25 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 1997 | 7276 | 0.010 |
Why?
|
Base Sequence | 1 | 2011 | 12797 | 0.010 |
Why?
|
Wnt1 Protein | 1 | 2000 | 118 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 21821 | 0.010 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2000 | 514 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2000 | 1723 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 85649 | 0.010 |
Why?
|
Wnt Proteins | 1 | 2000 | 721 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2000 | 1526 | 0.010 |
Why?
|
Postoperative Period | 1 | 2000 | 1839 | 0.010 |
Why?
|
beta Catenin | 1 | 2000 | 1058 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2000 | 4322 | 0.010 |
Why?
|
United States | 1 | 2020 | 69693 | 0.010 |
Why?
|
Transfection | 1 | 2000 | 5892 | 0.010 |
Why?
|
Preoperative Care | 1 | 2000 | 2245 | 0.010 |
Why?
|
Binding Sites | 1 | 2000 | 6115 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2000 | 6608 | 0.010 |
Why?
|
Recovery of Function | 1 | 2000 | 2924 | 0.010 |
Why?
|
Fibroblasts | 1 | 2000 | 4143 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2002 | 3839 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 2000 | 13814 | 0.000 |
Why?
|
Logistic Models | 1 | 2002 | 13403 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 2000 | 18112 | 0.000 |
Why?
|
Kidney | 1 | 2000 | 7167 | 0.000 |
Why?
|
Rats | 1 | 2000 | 24265 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2000 | 12071 | 0.000 |
Why?
|